Cargando…

Immunological alterations after immunotherapy with short lived HBV‐TCR T cells associates with long‐term treatment response in HBV‐HCC

The application of hepatitis B virus (HBV)–T‐cell receptor (TCR) T‐cell immunotherapy in patients with HBV‐related hepatocellular carcinoma (HBV‐HCC) has been apathetic, as the expression of HBV antigens by both normal HBV‐infected hepatocytes and HCC cells with HBV‐DNA integration increases the ris...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tan, Anthony Tanoto, Meng, Fanping, Jin, Jiehua, Zhang, Ji‐Yuan, Wang, Si‐Yu, Shi, Lei, Shi, Ming, Li, Yuanyuan, Xie, Yunbo, Liu, Li‐Min, Zhou, Chun‐Bao, Chua, Alicia, Ho, Zi Zong, Luan, Junqing, Zhao, Jinfang, Li, Jing, Wai, Lu‐En, Koh, Sarene, Wang, Tingting, Bertoletti, Antonio, Wang, Fu‐sheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8948543/ https://www.ncbi.nlm.nih.gov/pubmed/34935312 http://dx.doi.org/10.1002/hep4.1857

Ejemplares similares

Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells: results of dose escalation, phase I trial
por: Meng, Fanping, et al.
Publicado: (2021)

HBV-HCC treatment with mRNA electroporated HBV-TCR T cells
por: Tan, Anthony T, et al.
Publicado: (2021)

Lytic efficiency of immunosuppressive drug-resistant armoured T cells against circulating HBV-related HCC in whole blood
por: Lin, Meiyin, et al.
Publicado: (2023)

Correlation of HBV DNA and Hepatitis B Surface Antigen Levels With Tumor Response, Liver Function and Immunological Indicators in Liver Cancer Patients With HBV Infection Undergoing PD-1 Inhibition Combinational Therapy
por: Pan, Shida, et al.
Publicado: (2022)

Targeted Therapy of Hepatitis B Virus-Related Hepatocellular Carcinoma: Present and Future
por: Koh, Sarene, et al.
Publicado: (2016)

MicroRNAs Associated With HBV Infection And HBV-related HCC
por: Xie, Kun-Lin, et al.
Publicado: (2014)

Epigenetic regulation of HBV-specific tumor-infiltrating T cells in HBV-related HCC
por: You, Maojun, et al.
Publicado: (2023)

Human MAIT cells endowed with HBV specificity are cytotoxic and migrate towards HBV-HCC while retaining antimicrobial functions
por: Healy, Katie, et al.
Publicado: (2021)

HBV-Induced Immune Imbalance in the Development of HCC
por: Chen, Yongyan, et al.
Publicado: (2019)

HBV genome-enriched single cell sequencing revealed heterogeneity in HBV-driven hepatocellular carcinoma (HCC)
por: Wang, Wenhui, et al.
Publicado: (2022)

Challenges of CAR- and TCR-T cell–based therapy for chronic infections
por: Bertoletti, Antonio, et al.
Publicado: (2020)

TLR3 Plays Significant Roles against HBV-Associated HCC
por: Chen, Xiao-lan, et al.
Publicado: (2015)

Antiviral Treatments Eliminate the Adverse Impacts of High Baseline HBV Loads on the Survival of HBV-Related HCC Patients
por: Hu, Zili, et al.
Publicado: (2022)

HBV-Specific Adaptive Immunity
por: Bertoletti, Antonio, et al.
Publicado: (2009)

Viral integration drives multifocal HCC during the occult HBV infection
por: Chen, Xiao-Ping, et al.
Publicado: (2019)

Tenofovir vs Entecavir Among Patients With HBV-Related HCC After Resection
por: Li, Pengpeng, et al.
Publicado: (2023)

Single-cell analysis reveals HBV-specific PD-1(+)CD8(+) TRM cells in tumor borders are associated with HBV-related hepatic damage and fibrosis in HCC patients
por: Liu, Lulu, et al.
Publicado: (2023)

Deep sequencing of HBV pre-S region reveals high heterogeneity of HBV genotypes and associations of word pattern frequencies with HCC
por: Bai, Xin, et al.
Publicado: (2018)

Correction to: Viral integration drives multifocal HCC during the occult HBV infection
por: Chen, Xiao-Ping, et al.
Publicado: (2019)

Increasing antiviral treatment uptake improves survival in patients with HBV-related HCC
por: Hui, Vicki Wing-Ki, et al.
Publicado: (2020)

Editorial: Recent Advances in HBV and HCV Immunology
por: Dustin, Lynn B., et al.
Publicado: (2015)

Serum Iron Levels Decreased in Patients with HBV-Related Hepatocellular Carcinoma, as a Risk Factor for the Prognosis of HBV-Related HCC
por: Wei, Yanyan, et al.
Publicado: (2018)

Serum GGT/ALT ratio predicts vascular invasion in HBV-related HCC
por: Zhao, Zhifeng, et al.
Publicado: (2021)

Plasma lipids, tumor parameters and survival in HCC patients with HBV and HCV
por: Akkiz, H, et al.
Publicado: (2020)

Sorafenib in the Treatment of Virus-Related HCC: Differences Between HCV and HBV
por: De Matteis, Serena, et al.
Publicado: (2021)

Effects of antiviral therapy on post-hepatectomy HBV reactivation and liver function in HBV DNA-negative patients with HBV-related hepatocellular carcinoma
por: Gong, Wen-Feng, et al.
Publicado: (2017)

HBV‐integrated local genomic alterations reveal multicentric independent occurrences of multifocal HCC
por: Zou, Hao, et al.
Publicado: (2023)

Molecular Signature and Immune Landscape of HCV-Associated Hepatocellular Carcinoma (HCC): Differences and Similarities with HBV-HCC
por: De Battista, Davide, et al.
Publicado: (2021)

The Immunologic Role of Gut Microbiota in Patients with Chronic HBV Infection
por: Yang, Ruilin, et al.
Publicado: (2018)

Immunologic Characterization of Posthepatitis Cirrhosis Caused by HBV and HCV Infection
por: Li, Wan-Yu, et al.
Publicado: (2010)

Infected hematopoietic stem cells and with integrated HBV DNA generate defective T cells in chronic HBV infection patients
por: Shi, Y, et al.
Publicado: (2014)

In vivo therapeutic effects of affinity-improved-TCR engineered T-cells on HBV-related hepatocellular carcinoma
por: Liu, Qi, et al.
Publicado: (2020)

Intratumoral microbial heterogeneity affected tumor immune microenvironment and determined clinical outcome of HBV-related HCC
por: Li, Shengnan, et al.
Publicado: (2023)

HBV Induced HCC: Major Risk Factors from Genetic to Molecular Level
por: Ayub, Ambreen, et al.
Publicado: (2013)

T cell receptor-therapy in HBV-related hepatocellularcarcinoma
por: Bertoletti, Antonio, et al.
Publicado: (2015)

The Dynamic Role of NK Cells in Liver Cancers: Role in HCC and HBV Associated HCC and Its Therapeutic Implications
por: Sajid, Muhammad, et al.
Publicado: (2022)

Tenofovir is superior to entecavir in reducing HCC for patients with HBV-related compensated cirrhosis at high HCC risk scores
por: Huang, Yan, et al.
Publicado: (2022)

Tolerance and immunity to pathogens in early life: insights from HBV infection
por: Hong, Michelle, et al.
Publicado: (2017)

Fine‐Tuning TLR‐7‐Based Therapy for Functional HBV Cure
por: Bertoletti, Antonio, et al.
Publicado: (2019)

High-sensitivity HBV DNA test for the diagnosis of occult HBV infection: commonly used but not reliable
por: Wang, Chengwei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hgbks4q162po7dk7h7n5ks1e54